etaracizumab
Trade name: abegrin
mAbexperimental
Etaracizumab, also known as MEDI-522, trade name Abegrin, is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer, ovarian cancer and various other types of cancer. It is manufactured by MedImmune. — Wikipedia
Clinical trial activity
10 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2001 (NCT00263783)
Timeline
Indications
Mechanism of action
- Integrin alpha-V/beta-3ANTAGONIST
Integrin alpha-V/beta-3 antagonist
- Vitronectin receptor alphaINHIBITOR
ITGAV inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEtaracizumab ↗
- ChEMBLCHEMBL5314357 ↗
- ChEMBLCHEMBL1743014 ↗
Also known as
- abegrin
- abegrin
- abegrin vitaxin
- etaracizumab
- etaracizumab
- etaracizumab
- etaracizumab
- etaratuzumab
- hlm60
- medi-522
- medi-522
- medi-522
- vitaxin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00684996 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2008 | National Cancer Institute (NCI), Southwest Oncology Group |
| NCT00111696 | Phase 1 | May 1, 2005 | MedImmune, University of Pittsburgh |
| NCT00192517 | Phase 2 | Dec 1, 2003 | MedImmune |
| NCT00072930 | Phase 2 | Dec 1, 2003 | MedImmune |
| NCT00069017 | Phase 2 | Sep 1, 2003 | MedImmune |
| NCT00066196 | Phase 2 | Aug 1, 2003 | MedImmune |
| NCT00049712 | Phase 1 | Oct 1, 2002 | National Cancer Institute (NCI), University of Wisconsin |
| NCT00284817 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2001 | MedImmune |
| NCT00027729 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2001 | Cornell University, National Cancer Institute (NCI) |
| NCT00263783 | Phase 1 | Mar 1, 2001 | MedImmune |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 7 | 7 | 2 | 2001 |
| National Cancer Institute (NCI) | Government | 3 | 1 | 2 | 2001 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2001 |
| Southwest Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2002 |
6 organizations
Page 1 / 1